The company’s 13-valent Pneumococcal Conjugate Vaccine (PCV 13) has been selected for immunisation program in certain states, Pfizer Limited said in a statement.
Globally, pneumococcal disease is said to be one of the leading causes of deaths in children younger than five years of age. In India, according to industry sources, around 105,000 children died of pneumococcal pneumonia in 2010.
Also Read
In India, PCV 13 will be introduced in a multi-dose vial format, Pfizer said.
“With the introduction of PCV 13, we will able to help protect India’s birth cohort of 26 million children from the leading cause of child deaths in the country,” Pfizer India Country Manager S Sridhar said.
In the first phase, that will cover around 5.15 million babies, Pfizer Inc will supply the vaccine through UNICEF, under the auspices of Gavi.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)